Article
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Cell death & disease - 30 Jun 2016
Wu D-W, Chen T-C, Huang H-S, Lee H
Abstract excerpt
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show a clinical benefit when used to treat patients with EGFR-mutated non-small-cell lung cancer (NSCLC), but this treatment unfortunately fails in patients with TKI-resistant tumors. We here provide evidence that TC-N19 (N19), a novel dual inhibitor of EGFR and cMET, efficiently overcomes the EGFR-TKI resistance in EGFR-mutated NSCLC cells...
Topics
- Animals
- Anthraquinones
- Antineoplastic Agents
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Survival
- Drug Resistance, Neoplasm
- ErbB Receptors
- Gefitinib
- HSP90 Heat-Shock Proteins
- Humans
- Lung Neoplasms
- Mice, Inbred BALB C